On September 11, 2017, FDA is conducting a public meeting on Alopecia Areata Patient-Focused Drug Development. FDA is interested in obtaining patient input on the impact of alopecia areata, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.
This website will be updated as meeting materials are developed.
September 11, 2017
1pm – 5pm
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31 Conference Center (Great Room)
Silver Spring, MD 20993
(Information about arrival to FDA’s White Oak campus)
Public Docket: In addition to proving input at the public meeting, stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on November 13, 2017.
FDA is interested in patient responses to the questions listed in the Federal Register Notice.